Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds

Patent metadata

Field	Value
Publication number	US-11021456-B2
Application number	US-201916730085-A
Country	US
Kind code	B2
Filing date	Dec 30, 2019
Priority date	Jul 25, 2008
Publication date	Jun 1, 2021
Grant date	Jun 1, 2021

Abstract

Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the invention are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, and diseases characterized by abnormal growth, such as cancers. The invention further provides compositions containing the beta or gamma-amino isoquinoline amide compounds or substituted benzamide compounds.

First claim

What is claimed is:

1. A method of treating glaucoma, comprising ocular administration of a composition comprising a Rho kinase inhibitor and a pharmaceutically acceptable carrier to a subject in need thereof, wherein the administration is daily administration, weekly administration, or monthly administration and wherein the Rho kinase inhibitor is a compound of formula (I):

or a pharmaceutically acceptable salt thereof;
wherein
R 1 and R 2 are, independently, hydrogen, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 1 -C 4 carbonyl, or C 1 -C 4 carboxyl, or R 1 and R 2 combine to form a heterocycloalkyl ring of at least 5 and at most 8 member atoms, or R 1 and R 3 combine to form a heterocycloalkyl ring of at least 5 and at most 8 member atoms;
one of R 3 and R 4 is an aryl group, a heteroaryl group, a cycloalkyl group, a heterocycloalkyl group, C 1 -C 8 alkenyl, and the other of R 3 and R 4 is hydrogen or C 1 -C 4 alkyl; and
X 1 and X 2 are, independently, hydrogen, hydroxyl, halogen, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, amino, nitro, or cyano.

2. The method of claim 1 , wherein one of R 3 and R 4 is aryl or heteroaryl.

3. The method of claim 1 , wherein the amount of the Rho kinase inhibitor administered is about 0.01 to about 1,000 μg/kg subject body weight.

4. The method of claim 2 , wherein the amount of the Rho kinase inhibitor administered is about 0.01 to about 1,000 μg/kg subject body weight.

5. The method of claim 1 , wherein the amount of the Rho kinase inhibitor administered is about 0.1 to about 100 μg/kg subject body weight.

6. The method of claim 2 , wherein the amount of the Rho kinase inhibitor administered is about 0.1 to about 100 μg/kg subject body weight.

7. The method of claim 1 , wherein the amount of the Rho kinase inhibitor administered is about 1 to about 50 μg/kg subject body weight.

8. The method of claim 2 , wherein the amount of the Rho kinase inhibitor administered is about 1 to about 50 μg/kg subject body weight.

9. The method of claim 1 , wherein the administration is once daily, twice per day, or 4 times per day.

10. The method of claim 2 , wherein the administration is once daily, twice per day, or 4 times per day.

11. The method of claim 3 , wherein the administration is once daily, twice per day, or 4 times per day.

12. The method of claim 4 , wherein the administration is once daily, twice per day, or 4 times per day.

13. The method of claim 5 , wherein the administration is once daily, twice per day, or 4 times per day.

14. The method of claim 6 , wherein the administration is once daily, twice per day, or 4 times per day.

15. The method of claim 7 , wherein the administration is once daily, twice per day, or 4 times per day.

16. The method of claim 8 , wherein the administration is once daily, twice per day, or 4 times per day.

17. The method of claim 1 , wherein the administration is once weekly or twice weekly.

18. The method of claim 2 , wherein the administration is once weekly or twice weekly.

19. The method of claim 3 , wherein the administration is once weekly or twice weekly.

20. The method of claim 4 , wherein the administration is once weekly or twice weekly.

21. The method of claim 5 , wherein the administration is once weekly or twice weekly.

22. The method of claim 6 , wherein the administration is once weekly or twice weekly.

23. The method of claim 7 , wherein the administration is once weekly or twice weekly.

24. The method of claim 8 , wherein the administration is once weekly or twice weekly.

25. The method of claim 1 , wherein the administration is once a month.

26. The method of claim 2 , wherein the administration is once a month.

27. The method of claim 3 , wherein the administration is once a month.

28. The method of claim 4 , wherein the administration is once a month.

29. The method of claim 5 , wherein the administration is once a month.

30. The method of claim 6 , wherein the administration is once a month.

31. The method of claim 7 , wherein the administration is once a month.

32. The method of claim 8 , wherein the administration is once a month.

33. The method of claim 1 , wherein
R 1 and R 2 are hydrogen;
R 4 is C 6 H 5 ;
R 3 is hydrogen; and
X 1 and X 2 are hydrogen.

Assignees

• Aerie Pharmaceuticals Inc

Inventors

• Delong Mitchell A
• Sturdivant Jill Marie
• Royalty Susan M

Classifications

• C07D409/12

  linked by a chain containing hetero atoms as chain links · CPC title

• A61K31/381

  having five-membered rings · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• C07D333/24 Primary

  Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals · CPC title

• A61P1/00

  Drugs for disorders of the alimentary tract or the digestive system · CPC title